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Abstract
Background: Copy number variations (CNVs) are increasingly recognized as significant disease susceptibility markers in
many complex disorders including cancer. The availability of a large number of chromosomal copy number profiles in
both malignant and normal tissues in cancer patients presents an opportunity to characterize not only somatic
alterations but also germline CNVs, which may confer increased risk for cancer.
Results: We explored the germline CNVs in five cancer cohorts from the Cancer Genome Atlas (TCGA) consisting of
351 brain, 336 breast, 342 colorectal, 370 renal, and 314 ovarian cancers, genotyped on Affymetrix SNP6.0 arrays.
Comparing these to ~3000 normal controls from another study, our case–control association study revealed 39
genomic loci (9 brain, 3 breast, 4 colorectal, 11 renal, and 12 ovarian cancers) as potential candidates of tumor
susceptibility loci. Many of these loci are new and in some cases are associated with a substantial increase in disease
risk. The majority of the observed loci do not overlap with coding sequences; however, several observed genomic loci
overlap with known cancer genes including RET in brain cancers, ERBB2 in renal cell carcinomas, and DCC in ovarian
cancers, all of which have not been previously associated with germline changes in cancer.
Conclusions: This large-scale genome-wide association study for CNVs across multiple cancer types identified several
novel rare germline CNVs as cancer predisposing genomic loci. These loci can potentially serve as clinically useful
markers conferring increased cancer risk.
Keywords: Array CGH, DNA copy number, CNV association study, Cancer susceptibility
Introduction
The major sources of variation in the genomes of indi-
viduals include single nucleotide polymorphisms (SNPs),
small insertion or deletions (indels), and larger-scale
variations. The large-scale variants may be copy number
differences (gains or losses of chromosomal segments)
or copy number-neutral changes (such as inversions or
balanced chromosomal translocations). Copy number
variation (CNV) generally refers to large-scale (>1 kb)
chromosomal copy number changes, e.g., amplifications
or deletions compared to a reference genome [1], although
the size distinction is an artificial one defined by the
limitations of previous CNV detection methods. Genome-
wide CNV screening methods using high-resolution
oligonucleotide-based microarrays and more recently,
high-throughput sequencing have accelerated the cata-
loguing and characterization of large genomic variants.
Initial CNV studies reported a greater than expected
variability in genomic CNVs in the normal human popu-
lation, i.e., a significant fraction of individual human ge-
nomes may be different from each other [2-4]. In 2006,
the first large-scale population map of CNVs was con-
structed, with estimates that up to 12% of the human
genome may harbor CNVs [3]. Recent updates from the
Database of Genomic Variants (DGV) estimate CNVs to
encompass up to 22% of the human reference genome,
making them the most prevalent type (by size) of
genomic variability between individuals [4]. In the early
days, the focus of genome-wide association studies
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(GWAS) was to identify disease-associated SNPs. How-
ever, as the array platforms and the algorithms for infer-
ring CNVs from the same arrays have improved, more
recent studies have identified a number of germline
CNVs as potential susceptibility loci for a range of
diseases including infectious, autoimmune, and neuro-
psychiatric diseases, as well as cancer [5-8].
Multiple germline CNVs have been reported as factors
predisposing individuals towards cancer pathogenesis.
For example, CNVs at 3p25 and 2p24.3 were associated
with the aggressiveness of prostate cancer [9,10]. Dele-
tions and rearrangements in the BRCA family of genes
have been implicated in breast and ovarian cancers
[11,12]. Deletions of GSTM1 and GSTT1 were shown to
decrease the 5-year cancer survival rates for bladder and
prostate cancers in the Dutch general population [13]. A
recent large-scale CNV association study revealed that
CNVs at 1q21.1 involving the NBPF family of genes were
found to predispose individuals to neuroblastoma [14].
In this study, we identified recurrent germline CNVs
in cancer patients from the Cancer Genome Atlas
(TCGA) [15-18] that may be associated with increased
susceptibility for cancer. For five major types of human
cancers (breast invasive carcinomas [15], colorectal can-
cers [16], glioblastoma multiforme [17], ovarian serous
cystadenocarcinomas [18], and renal cell carcinomas
[19]), germline CNV calls from each cancer cohort was
compared to a normal control population obtained from
an unrelated large GWAS study [20]. Our results provide
an initial catalog of germline CNVs that are associated
with an individual’s predisposition to specific cancers and
may serve as biomarkers in cancer screening.
Results and discussion
Study design
The Cancer Genome Atlas (TCGA) has aimed to iden-
tify and catalog major cancer-causing genomic changes
by profiling 500 patients for each of ~20 cancer types.
For each patient, DNA from tumor and matched control
were profiled, with peripheral blood as the control in
most cases and a non-tumor tissue in a small subset of
cases. With the project near completion, it has provided
access to an unprecedented amount of genomic profiling
data from cancer patients, including exome sequencing
for most cases, whole-genome sequencing (~10% of
cases in many tumor types), RNA and microRNA ex-
pression, DNA methylation at CpG islands, and DNA
copy number. To characterize CNVs, every sample was
profiled on Affymetrix SNP 6.0 arrays. In the pilot phase
of the project, the same samples were also profiled on
Illumina and Agilent arrays; later on, low-pass whole-
genome sequencing (6-8X) was also utilized but only for
a subset of the cases. For this study, we focused on
germline copy number profiles estimated from the
Affymetrix SNP 6.0 platform because it allows us to
examine the largest number of cases as well as having
the highest probe density (~1 million probes primarily
for SNP detection and another ~1 million for CNVs).
We chose cancer types with at least 400 normal sam-
ples at the beginning of our study, resulting in a total
of 1,779 cases across the five cancer types mentioned
earlier. The raw data were downloaded from the Cancer
Genome Atlas data portal (https://tcga-data.nci.nih.
gov/tcga/).
One of the challenges in our analysis was to identify a
proper control dataset. First, it was important to find a
dataset with sufficiently large sample size to detect rare
variants. Studies from the 1000 Genomes project have
found that rare genomic variants vastly outnumber com-
mon variants [8], identifying approximately 20,000 CNVs
with frequencies down to 1% [21,22]. Without a large
enough control set, CNVs identified from TCGA germ-
line samples may include rare variants in the population
not related to cancer. Second, assessment of CNVs can
be confounded by differences in array platforms and
methods of analysis [23]. Thus it was necessary that the
control subjects were profiled on the same Affymetrix
SNP6.0 platform, processed using the same analytical
parameters. Third, analysis results can also be con-
founded by ethnic backgrounds [23-26]. To minimize
this effect, we limited our analysis to individuals of
Western European descent, due to low numbers of
samples available for other ethnicities, and had to use a
control set from a similar population; we also ensured
that the results were not spurious due to ethnicity differ-
ences using principal component analysis. Finally, we
have found that most GWAS studies make genotype
calls available but not raw data, even after publication.
For the current study, it was necessary to access the raw
data, so that we could process both cancer and control
data uniformly from the start. After an extensive search
for healthy human controls, we converged on the
data available from the Myocardial Infarction Genetics
Consortium (MIGEN), which had over 3,074 healthy
controls generated on the Affymetrix SNP 6.0 platform.
The data was obtained from dbGAP and from the
investigators on the project. For this dataset, the samples
were drawn from six collection sites: Boston, MA; Seattle,
WA; Helsinki, Finland; Malmö, Sweden; Barcelona, Spain;
and Milan, Italy [20].
Identification of copy number variable regions
An overview of the data and analysis steps are shown in
Figure 1. To identify CNVs, we used the PennCNV [27]
software package. This algorithm employs a hidden
Markov model to segment the total signal intensity for
both alleles (log R ratio, or LRR) and allelic intensity
ratio between the two alleles (B allele frequency, or
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BAF) for each probe across the genome. Additional
sources of information such as probe spacing and
population allele frequency are also incorporated.
Across all five cancers, we identified 88,910 CNVs
from 1,779 patients with a median CNV count of 15
gains and 32 losses per patient. The median length of
these CNVs was 53.79 kb and 17.34 kb for gains and
losses, respectively. For our control population, we
included 3,074 Western European patients producing a
total of 161,910 CNVs, which had a median CNV count
of 18 gains and 34 losses per sample. Although the
median and the standard deviation (SD) of the CNV
number per sample were similar between the control
and case, one brain cancer patient showed a very high
CNV count (701 CNVs), resulting in a very large
standard deviation (SD = 40.7) for the GBM category.
The standard deviation for GBMs becomes comparable
(SD = 20.7) to those of other tumor types and controls
when it is recalculated without this patient. Summaries of
the dataset and characteristics are described in Table 1.
To merge individual CNVs into common CNV regions
(CNVR), we used CNVruler [28], which is one of the
few tools that integrate multiple methods for calculating
CNVRs, with several statistical association tests and
options for population stratification. To identify regions
significantly associated with risk of individual cancers,
the frequencies of specific CNVRs were compared be-
tween each cancer cohort and the MIGEN control group
using Fisher’s exact test. To detect potential association,
we used the significance level of P < 1 × 10−4. Given that
the number of CNVRs is generally smaller than 500,
this p-value threshold is more conservative than the
Bonferroni correction on P = 0.05. Amplified and deleted
CNVRs were calculated separately. A total of 75 rare
and common CNVRs were significantly associated with
at least one of the cancers studied.
To assess their possible phenotypic impact, we com-
pared the CNVRs to known genomic imbalances col-
lected in the Database of Genomic Variants (DGV) [29].
The DGV release we utilized includes 290,000 CNVs
Figure 1 Workflow for our CNV analysis. The numbers of samples at various steps are indicated.
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from 8802 samples compiled from 53 studies, covering
66.5% of the human genome [4]. In principle, cancer-
specific CNVRs found in DGV reduces the likelihood of
the region being causative. However, since DGV is not a
curated database and integrates data from multiple plat-
forms with significantly varying probe coverage and res-
olutions, many variants are known to have inaccurate
boundaries, overestimated sizes [24,30] and misleading
frequencies [31], while regions identified in many studies
or by multiple independent methods are most likely real.
We therefore filtered common CNVRs found in multiple
studies and samples from DGV and obtained a total of
39 rare CNVRs that are associated with cancer risk for
the five cancers. The full list of significant germline
CNVRs is shown in Table 2.
There are over 200 inherited cancer syndromes that
account for 5-10% of all cancer cases [32]. However, all
known cancer susceptibility genes account for only 1%
to 15% of familial cancers [33]. Therefore, a large frac-
tion of variants that increase genetic predisposition in
hereditary cancers remains to be uncovered. Common
CNVRs are unlikely to be associated with disease [34],
but highly penetrant rare CNVRs are likely to increase
cancer susceptibility [30]. With our larger sample size
compared to previous case–control association studies,
we have greater statistical power to identify novel germ-
line CNVRs associated with cancer.
Breast invasive carcinoma
Breast cancer is the most common female malignancy in
the world, with more than 1.3 million cases and over
450,000 deaths each year [35]. One in eight women in
the United States is diagnosed with breast cancer and it
accounts for 30% of all female cancers [36]. It is a com-
plex genetic disease where up to a quarter of all cases
are likely to be hereditary [33]. Genomic gains and losses
in BRCA1/BRCA2 have been reported to increase pre-
disposition for hereditary breast and ovarian cancers
[11,12,37]. CNVs at 17q11.2, 11q13.1, and 6q24.1 were
recently reported to be strongly associated with breast
cancer recurrence [38]. Inheritable syndromes including
Li-Fraumeni syndrome (LFS) and Peutz-Jeghers syn-
drome (PJS) have genomic rearrangements in TP53 and
STK11, respectively, that increase risk of early onset
cancers including breast [39,40]. Clinically relevant
mutations in BRCA1, BRCA2, TP53, and PTEN are well
recognized but only account for 5-10% of all new cases,
leaving a large fraction of genetic predisposition to be
uncovered [41].
Our analysis of germline CNVs for 336 breast cancer
patients revealed 10,408 CNVs as losses and 5,428 as
gains (median count of 15 gains and 31 losses per indi-
vidual). We found three CNVR losses significantly
enriched in the germline of breast cancer patients:
11p11.12, 3p14.2, and 3p24.1. The deletion at 11p11.12
was detected in five breast cancer patients (the length
of CNVR is 8 kb) but not observed in the control set
(P = 1.08 x 10−5). The deletion at 3p14.2 (30 kb in
length) was observed in 1.8% (6/336) of cases and
0.07% (2/2956) in the control population (P = 2.54 x 10−5,
odds ratio (OR) = 26.85). The deletion at 3p24.1 was 3 kb
in length and was observed in 2.1% (7/336) of the cases
and 0.16% (5/2956) in the controls (P = 5.47 x 10−5, OR =
12.57). None of these deletions showed overlap with
known coding sequences. In addition, we analyzed the as-
sociation between the observed germline variants and
disease subtypes (luminal A and B, basal, and HER2
molecular subtypes as reported by the TCGA con-
sortium) [15]. Among the three susceptible loci, the
deletion at 3p24.1 were observed only for the patients
categorized as luminal A type (P = 0.0339, Fisher’s exact
test).
Colorectal cancers
Colon cancer is the fourth most commonly diagnosed
malignancy and the second leading cause of cancer-
related mortality worldwide with a 6% lifetime risk in
the United States [36]. The present estimate is that 15–
30% of cases may have a major hereditary component
[42,43]. CNVRs associated with colon cancer have been
found in multiple inherited colorectal tumor syndromes:
large deletions in APC confer increased risk for patients
Table 1 Characterization of CNVs for each cancer and control sets
Tumor type Samples aFiltered samples (blood/adjacent) CNVs bCNVR (no) CNV size (bp, mean) cMedian Mean SD
Breast (BRCA) 555 336 (270/66) 15836 9440 105943 46 47.1 14.2
Brain (GBM) 524 351 (344/7) 18072 9286 111178 45 51.5 40.7
Colon (COAD) 444 342 (262/80) 17830 9463 93777 49 52.1 17.1
Kidney (KIRC) 505 370 (51/319) 17968 9574 99424 47 48.6 13.7
Ovarian (OV) 514 380 (314/66) 19204 9777 95492 47 50.5 26.1
Control (MIGEN) 3074 2956 161910 79389 52 54.8 20.5
aFiltered samples are the number of cases after the exclusion of low-quality samples. The cases are categorized according to their source of normal tissues (blood
or adjacent normal tissues). bCNVR are the number of CNVRs assessed in each of the five association studies with control (MIGEN). cThe median, mean and standard
deviation (SD) of the number of CNVs per individual are shown.
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Table 2 Significant cancer germline copy number variable regions
Cancer Chr Start Size Freq (control) Freq (case) Type OR P-valuea P-value (PCA)b Gene(s)c
BRCA 11 51185363 8472 0% 1.49% Loss - 1.08E-05 9.66E-01
BRCA 3 62936471 30079 0.07% 1.79% Loss 26.85 2.54E-05 1.05E-04
BRCA 3 26586501 3489 0.17% 2.08% Loss 12.56 5.47E-05 3.44E-06
COAD 3 107601890 16832 0.03% 2.34% Loss 70.78 1.02E-07 4.90E-05
COAD 10 101261779 22068 0% 1.46% Loss - 1.20E-06 9.63E-01 NKX2-3
COAD 4 156797864 71044 0.24% 2.34% Loss 10.09 4.13E-05 9.20E-06 GUCY1A3
COAD 7 29635116 120414 0.03% 1.46% Gain 43.84 6.41E-05 6.13E-04 DPY19L2P3, LOC100271874, LOC646762
GBM 14 21685305 117313 0.30% 5.41% Loss 18.74 5.54E-13 6.54E-12 TRA@, TRD
GBM 5 57361784 7507 16.50% 33.00% Loss 2.5 1.54E-12 2.52E-20
GBM 22 47288391 152640 0.07% 2.85% Loss 43.31 8.76E-09 6.97E-06 FAM19A5
GBM 7 38257218 88038 0.84% 5.41% Loss 6.71 2.25E-08 1.24E-09 TARP
GBM 5 10927644 15240 0% 1.99% Loss - 1.44E-07 9.60E-01
GBM 14 21804698 2132 0.10% 2.28% Loss 22.96 1.85E-06 1.42E-05 TRA@, TRD
GBM 14 21681152 2379 0.20% 2.56% Loss 12.94 4.34E-06 6.42E-06 TRA@, TRD
GBM 10 42882051 56351 0.30% 2.56% Loss 8.62 3.15E-05 3.75E-06 RET
GBM 7 61793773 26492 1.56% 5.13% Loss 3.42 6.89E-05 5.00E-07
KIRC 14 21681152 2379 0.20% 5.41% Loss 28.1 6.44E-15 3.49E-12 TRA@, TRD
KIRC 10 96855083 4614 0.07% 3.24% Loss 49.51 2.26E-10 1.23E-07
KIRC 3 89250592 142689 0% 1.62% Gain - 1.83E-06 9.63E-01 EPHA3
KIRC 2 97429511 99111 2.17% 7.03% Loss 3.42 2.33E-06 1.26E-08 ANKRD36B
KIRC 6 118470482 5095 0.24% 2.43% Loss 10.5 1.33E-05 3.52E-06 SLC35F1
KIRC 17 34990311 173216 0.64% 3.51% Gain 5.63 1.56E-05 1.54E-05 C17orf37, ERBB2, GRB7, NEUROD2, PGAP3,
PNMT, PPP1R1B, STARD3, TCAP
KIRC 4 103363913 68353 0.10% 1.89% Loss 18.99 1.78E-05 4.83E-05 SLC39A8
KIRC 2 91049141 1293 0.58% 3.24% Loss 5.79 2.68E-05 3.67E-06
KIRC 4 2281 109282 3.45% 8.38% Gain 2.56 5.16E-05 2.94E-06 ZNF595, ZNF718
KIRC 7 19542080 79082 0.04% 1.35% Loss 40.48 9.06E-05 6.47E-04
KIRC 12 130123182 31743 0.04% 1.35% Loss 40.48 9.06E-05 1.11E-03 GPR133
OV 13 54589383 6308 0.07% 2.37% Loss 35.83 1.32E-07 1.13E-05
OV 4 36584413 19612 0.03% 2.11% Loss 63.55 2.15E-07 1.52E-04
OV 1 244904225 32016 0% 1.84% Gain - 2.37E-07 9.60E-01
OV 10 66977929 15004 4.57% 11.60% Gain 2.74 3.29E-07 3.64E-11
OV 2 192993 16566 0% 1.58% Gain - 2.11E-06 9.63E-01 SH3YL1
OV 1 229982231 47730 0% 1.58% Gain - 2.11E-06 9.63E-01 DISC1, DISC2, TSNAX-DISC1
OV 2 7529134 41988 0% 1.58% Gain - 2.11E-06 9.63E-01
OV 10 495985 75956 0% 1.32% Gain - 1.87E-05 9.47E-01 DIP2C
OV 5 174076632 49822 0% 1.32% Gain - 1.87E-05 9.47E-01 MSX2
OV 18 48381779 37120 0% 1.32% Gain - 1.87E-05 9.48E-01 DCC
OV 18 45329306 46009 0% 1.32% Gain - 1.87E-05 9.47E-01 LIPG
OV 4 172611459 3050 4.63% 10.00% Loss 2.29 6.75E-05 1.95E-09
aThe P-value is based on two-tailed Fisher’s exact test comparing gain and loss frequency in cases versus controls using a threshold of 10−4. bThe significance
estimated in a regression analysis using the first component of principal component analysis as covariates. cOverlapping genes with CNVRs (in either case or
control) were determined using Refseq as the annotation source.
Park et al. Molecular Cancer  (2015) 14:25 Page 5 of 12
Figure 2 (See legend on next page.)
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with familial adenomatous polyposis coli (FAP) [44]; a
CNVR at 3p26 is associated with APC mutation negative
familial colorectal cancer [10]; hereditary non-polyposis
colorectal cancer (HNPCC or Lynch syndrome) ac-
counts for 5% of colon cancers with predisposing CNV
deletions in PMS2, MLH1, MSH2, and MSH6 [37,45-48];
and genomic rearrangements in STK11 increase risk of
early onset cancers including colon in patients with
Peutz-Jeghers syndrome (PJS) [40].
We identified 12,031 CNVs as losses and 5,799 as
gains from 342 genomes of colon cancer patients (me-
dian count of 15 gains and 34 losses per individual).
Four significant regions associated with colon cancer
were identified at 3q13.11, 10q24.2, and 4q32.1 as losses
and at 7p15.1 as a gain. The most significant deletion of
3q13.11 was 16 kb in length and did not overlap with
any coding sequences. It was observed in 2.3% (8/342) of
cases and 0.03% (1/2956) of controls (P = 1.02 x 10−7,
OR = 70.78). The 10q24.2 deletion was 22 kb in size and
occurred in 1.75% (6/342) of cases but not observed
in the control set (P = 1.2 x 10−7). Of the six cases, a
loss involving the first exon and 5′ untranslated re-
gions (UTR) of NKX2-3 was observed for four pa-
tients (Figure 2A). NKX2-3 encodes a homeodomain
containing a transcription factor. Its variants have
been previously reported to be associated with inflam-
matory bowel diseases, the premalignant disorder of
colorectal cancers [49,50]. The deletion at 4q32.1 in-
volving GUCY1A3 was observed in eight colorectal
cancer patients (P = 4.13 x 10−5, OR = 10.09). Large
CNVs (~120 kb) on gain of 7p15.1 encompassing sev-
eral genes DPY19L2P3, LOC100271874, LOC646762
were observed in five colorectal patients (1.46%) while
only observed in the control set once (P = 6.41 x 10−5,
OR = 43.84).
Glioblastoma multiforme
Glioblastoma multiforme (GBM) is the most deadly sub-
type of brain tumors in adults. In 2012, 22,910 Americans
were estimated to have been diagnosed and 13,700 were
estimated to have died from brain and other nervous sys-
tem cancers [36]. GBMs are currently incurable and are
responsible for a disproportionately share of cancer mor-
tality with patients typically surviving less than 18 months
[51]. Approximately 5% of patients have a family history
including rare genetic syndromes including Li-Fraumeni
syndrome where genomic rearrangements in TP53 were
associated with elevated brain cancer risk [39]. Germline
duplications in SMARCB1 are associated with increased
risk of malignant rhabdoid tumors (MRT) found in the
brain [52]. It has also been suggested that hemizygous
germline deletions of 22q are possible predisposition loci
for GBM [53].
We identified 12,875 CNVs as losses and 5,197 as
gains (median count of 13 gains and 32 losses per indi-
vidual) from 351 genomes of GBM patients. A total of
nine significant CNVRs associated with brain malignan-
cies were observed. All associations were identified as
genomic losses. Four deletions (one at 7p14.1 and three
at 14q11.2) overlapped with genomic loci encoding T
cell receptors (TCR) including the most significant
involving TCR-alpha that occurred in 5.4% (19/351) of
cases 0.3% (9/2956) of controls (P = 5.54 x 10−12, OR =
18.74). These deletions overlap with known regions asso-
ciated with less aggressive forms of neuroblastoma [14].
The deletions at 5q11.2 were recurrent in case (33%;
116/351) and control populations (16.5%; 487/2956)
(P = 1.54 x 10−12, OR = 2.5), but did not involve known
coding regions. The deletion observed at 22q13.32 over-
laps with FAM19A5, the association of which was previ-
ously observed with pancreatic cancers [54]. This
deletion was observed in 2.8% (10/351) of cases and
0.07% (2/2956) of controls (P = 8.76 x 10−9, OR = 43.31).
Other deletions associated with GBM (~15 kb at 5p14.2
and ~26 kb at 7q11.21) did not involve coding regions.
The association of deletions involving the RET proto-
oncogene with GBM was observed. The deletions oc-
curred in 2.6% (9/351) of cases and 0.3% (9/2956) of the
controls (P = 3.15 x 10−5, OR = 8.62) (Figure 2B). RET
encodes a receptor tyrosine kinase, which plays an im-
portant role in neural development [55] and has been
implicated in neuroblastoma [56] and thyroid cancers
[57]. Given the presumptive oncogenic role of RET in
those tumors, how the germline deletion of RET may
serve as a susceptibility locus is not clear. It is possible
that the germline dosage changes of RET may have
broad implications as shown for their association with
Hirschsprung’s disease [58] or this variant is linked to
other causal genomic loci. It has also been shown in
several examples that the same gene may act as an
(See figure on previous page.)
Figure 2 Illustrative examples of rare germline CNVRs over-represented in specific cancers. In each panel, the first two tracks after the
genomic coordinates show the RefSeq gene annotations and the positions of the probles on the Affymetrix SNP6.0 arrays. Below that, germline
CNVs for cancers cases are indicated in blue (losses) and red (gains), followed by CNVs observed in control individuals in black. (A) 22 kb loss
affecting NKX2-3 in 6 colorectal cancer cases (n = 342); none is present in the controls (n = 2956). (B) 56 kb loss affecting RET in 9 glioblastoma
patients; 9 CNVs are also found in the controls but the sample size of the control set is almost 10-fold greater (351 vs 2956), making this statistically
significant. (C) 173 kb gain affecting ERBB2 in 13 kidney cancer cases (n = 370); 19 are present in the controls. (D) 37 kb gain affecting DCC in five
ovarian cancer cases (n = 380); none are present in the controls.
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oncogene or a tumor suppressor depending on its
cellular context [59-62].
Renal clear cell carcinoma
Renal clear cell carcinoma is the most common type of
kidney cancer, which accounts for 3-5% of all adult ma-
lignancies [36]. It is the sixth most common in cancer in
men and eighth most common in woman. Approxi-
mately 2-3% of cases are hereditary, including several
autosomal dominant syndromes [63]. Germline deletions
in VHL are associated with Von Hippel-Lindau (VHL)
disease, which is characterized by the development of
multiple vascular tumors including the kidney [64]. Rare
full gene deletions of FH predispose individuals to her-
editary leiomyomatosis and renal cell cancer (HLRCC)
[65]. Children with malignant rhabhoid tumors (MRT), a
particularly aggressive pediatric kidney cancer, have
found germline duplications in SMARCB1 associated
with increased cancer risk [52]. Large genomic deletions
and rearrangements in TSC1 and TSC2 in tuberous
sclerosis contribute to harmartomas found in multiple
organs including the kidney [66].
We identified 12,242 CNVs as losses and 5,726 as
gains (median count of 15 gains and 32 losses per indi-
vidual) from 370 genomes of renal cell carcinoma (clear
type). Eleven significant CNVRs were associated with
kidney cancer, with eight loss CNVRs and three gain
CNVRs. The most significant CNVR occurred as a de-
letion at 14q11.2 involving genomic loci encoding
TCR-alpha (P = 6.44 x 10−15, OR = 28.09). The second
significant locus was observed at 10q23.33 (P = 2.26 x
10−10, OR = 49.50) without involving coding sequences.
Some of the significant loss CNVRs did involve coding se-
quences. For example, deletions involving ANKRD36B
on 2q11.2 occurred in 7.0% (26/370) of cases and 2.16%
(64/2956) of controls (P = 2.33 x 10−6, OR = 3.41). Dele-
tions involving solute carrier family-coding regions
were observed at two genomic loci: 6q22.2 (SLC35F1;
P = 1.33 x 10−5, OR = 10.5) and 4q24 (SLC39A8; P =
1.78 x 10−5, OR = 18.98). Five patients showed deletions
involving the locus encoding G protein-coupled recep-
tor 133 (GPR133), while only one control individual
showed it (P = 9.06 x 10−5, OR = 40.48). The remaining
CNVRs observed at 2p11.1 and 7p15.3 (observed in
3.2% and 1.4% of cases, respectively) did not overlap
with any genes.
The gains at 3p11.2, 17q12, and 4p16.3 were signifi-
cantly enriched in kidney cancer patients. A CNVR in
3p11.2 encompassing EPHA3 was observed for six can-
cer patients (1.6%) and was not found in the control
population (P = 1.83 x 10−6). A gain at 17q12 overlaps
with the cancer-related gene ERBB2. Interestingly, germ-
line amplifications in cancer patients are localized to
ERBB2, while many controls have larger CNVs in the
same region (Figure 2C). The biological implication of
germline amplification involving ERBB2 is not well
understood. However, the known roles of somatic ampli-
fication in certain tumor types such as breast cancer
raises a hypothesis that different germline copy numbers
of ERBB2 may be a predisposing factor in the affected
individuals. The other gain of 109 kb in 4p16.3 overlap-
ping with ZNF595 and ZNF718 occurred in 8.4% (31/370)
of cases and 3.4% (102/2956) of controls (P = 5.16 x 10−5,
OR = 2.56).
Ovarian serous cystadenocarcinoma
Ovarian cancer is the fourth most frequent cancer in
woman worldwide. In the United States, approximately
22,910 women will be newly diagnosed resulting in
15,500 deaths per year [36]. At least 10% of ovarian
tumors are hereditary and associated with autosomal
dominant syndromes [67]. Rare hereditary syndromes
including Peutz-Jeghers syndrome (PJS) and Gorlin syn-
drome have germline deletions in STK11 and Patch
genes, respectively, that increase the risk of early onset
ovarian cancer [40,68]. Germline copy number variants
in BRCA1 and BRCA2 are known to increase risk of
hereditary breast/ovarian cancers independent of their
BRCA1/BRCA2 mutation status [37,69].
Our analysis revealed a total of 12,612 CNVs as losses
and 6,592 as gains in 380 ovarian cancer patients (median
count of 15 gains and 32 losses per individual). A total of
12 genomic loci showed significant association with ovar-
ian cancer, nine of which were gains and three were losses.
Six of the 12 genomic loci were observed in coding re-
gions. Two gain CNVRs including a 16 kb segment in gen-
omic loci encoding SH3YL1 (2p25.3) and a 47 kb region
overlapping with DISC1, DISC2, and TSNAX-DISC1
(1q42.2) were observed at the same frequency of 1.6%
(6/380) but not observed in the controls (P = 2.11 x 10−6).
Genomic loci encoding DIP2C (chr10), MSX2 (chr5),
DCC (chr18), and LIPG (chr18) also showed similar fre-
quencies in the ovarian cancer patients of 1.3% (5/380)
but not in the control (P = 1.87 x 10−5). Among them, the
association with DCC and ovarian cancer pathogenesis
has been previously reported [70] (Figure 2D).
Additional analysis and limitations of this study
It is possible that some variants are shared in multiple
tumors types but their effect sizes are too small to be de-
tected in a single-tumor analysis. When we carry out the
same analysis on the aggregate data, we indeed can iden-
tify more loci of potential interest. Of the 17 loci identi-
fied this way, 8 were found with single-tumor analysis
but 9 were not. Of these 9, 4 overlapped with genes, in-
cluding TFG, TP53TG3 and HLA loci. The list is shown
in (Additional file 1: Table S1). Moreover, we focused
our analysis above on discovering tumor susceptibility
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markers by selecting genomic variants with OR > 1. But
we could also search for potentially protective loci by
applying the criterion OR < 1. This analysis results in a
list of 17 genomic variants (Additional file 2: Table S2),
which are all non-coding.
One way to examine potential impact of identified
CNVs is to determine whether the differential copy
numbers between the samples that carried a CNV and
those that did not resulted in a significant difference in
gene expression. Proper analysis of this question, how-
ever, requires expression profiles of matched normal tis-
sues, when TCGA data only contain expression levels
(either RNA-seq or arrays) of the tumor tissues due to
the difficulties of obtaining adjacent tissues for RNA
analysis. When we limit our analysis to expression data
from tumor tissues, it is unlikely to be informative. For
instance, we explored whether the CNV at 17q12 may
influence the gene expression of ERBB2 in the cancer
cells, and found that it was not significantly different be-
tween the tumors harboring this genomic variants and
those without (P = 0.546; t-test). This result, however,
does not imply that the germline variant was not func-
tional, as many factors downstream would have contrib-
uted to the ERBB2 expression in tumor cells.
Our analysis has generated a list of CNVs that are sig-
nificantly associated with cancer risk based on a large
number of samples. However, there are several caveats
in this computational study. First, before these genes can
be utilized as clinical markers, they need to be further
validated with PCR or other assays. Such experimental
validation was not possible in our study due to the fact
that consortium projects are not able to provide DNA
samples for individual studies. Future studies on inde-
pendent cohorts will also be necessary before these
markers can be utilized. Second, although we have paid
a great deal of attention to the bioinformatics aspect
(e.g., re-processing case and control datasets from raw
data to remove computational artifacts), it is possible
that some of the CNVs may be rare variants that hap-
pened to be present at lower frequency in the particu-
lar control dataset we had. This may be due to chance
or to any bias that may have occurred in sample collec-
tion, including patient characteristics such as race and
age. Our selection of Caucasian patients from sample
annotations and principal componenet analysis allevi-
ates bias due to differences in population structure,
but it may not have been removed completely. Third,
it remains possible that the reported variants are not
causal variants but are linked to the true causal vari-
ants. Functional in vitro or in vivo studies on the im-
pact of specific CNVs will be needed for a better
understanding of causal relationships. Finally, the list
derived in this work is clearly incomplete. Although
Affymetrix SNP arrays have been extensively used in
the field, they are not able to detect small CNVs; many
variants were undoubtedly missed also due to the low
frequency of many of these CNVs. Subsequent studies
on larger populations using exome or whole-genome
sequencing data will be needed for more complete
lists.
Conclusion
This study provides a new catalogue of over-represented
germline CNVs that potentially contribute to cancer risk,
utilizing a publicly available dataset of a large population
of cancer patients across multiple cancer types. As ex-
pected, most candidate prognostic CNVs we find have
low frequencies despite their statistical significance.
Among the most interesting cases are the rare germline
CNVs affecting RET in GBMs, ERBB2 in renal cell car-
cinomas, and DCC in ovarian cancers. Although causal
relationship should be tested in independent cohorts in
the future, these CNVs may explain some of the disease
heritability not previously identified. Interestingly, few
CNVs associated with disease risk are shared among
cancers, suggesting that either there is a diversity of
pathways through which germline CNVs confer cancer
risks or our sample size is still too small to detect such
low frequency events. Further studies profiling other
germline characteristics, such as epigenetic alterations
and combined effects of multiple variants, will also be




Genotyping was performed using the Affymetrix SNP
6.0 arrays in the TCGA consortium. Cases are germline-
derived DNA samples (peripheral blood or adjacent
tissues) of European ancestry; raw . CEL files were
downloaded from The Cancer Genome Atlas Data
Portal (https://tcga-data.nci.nih.gov) in May 2012.
Control samples were obtained from the Myocardial
Infarction Genetics Consortium (MIGEN) (phs000294.
v1.p1) [20]. Raw CEL files for healthy controls of
European ancestry (n = 3,074) were kindly provided by
the investigators of that project.
CNV detection
CNVs were called using the PennCNV-Affy6 protocol
(2011 Jun16 version) on genome build hg18 (http://
www.openbioinformatics.org/penncnv/). PennCNV uses
a hidden Markov model that incorporates Log R Ratio
(LRR) values, B Allele Frequency, SNP spacing, and
population frequency to generate CNV calls for each
sample [27]. Low quality samples were eliminated from
subsequent analysis using defaults in PennCNVs filter_cnv.
pl program in addition to filtering samples with a standard
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deviation of normalized intensity (LRR) > 0.35. The LRR is
a normalized measure of total signal intensity for two
alleles of a SNP.
CNVR detection and association testing
Illustrative examples of germline CNVRs are shown in
Figure 2 with the remaining CNVRs (in Table 2) illus-
trated in (Additional file 3: Figure S1). CNVRuler (v1.3)
was used to merge individual CNVs into common CNV
regions (CNVR) for each cancer and control set [28].
CNVRs that did not have a recurrence of > 0.1 were fil-
tered from the list. CNVR frequencies between each
cancer set and controls were evaluated using two-tailed
Fisher’s exact test. Significant (P < 1.0 x 10−4) differences
were considered as potential associations. The signifi-
cance of association was also calculated by using the first
component from PCA as a covariate in CNVRuler. PCA
analysis was performed using the CNV calls on the
CNVR markers for each of the five cancer types [71].
The scatter plots of the first and second principle compo-
nents show no population stratification in the controls and
cases for the five cancer types (Additional file 4: Figure S2).
The overlap with known CNVs was determined by count-
ing the number of times each CNVR was observed in the
Database of Genomic Variants (DGV) using Release 2012-
03-29 [4]. Since CNV boundaries defined by DGV are
known to be variable and not entirely accurate, we classi-
fied CNVRs observed in fewer than 100 individuals as a
rare event.
Additional files
Additional file 1: Table S1. Germline variants identified in the pooled
cancer cases.
Additional file 2: Table S2. Protective genomic loci with OR < 1.
Additional file 3: Figure S1. Graphical representation of all the CNVRs.
Additional file 4: Figure S2. The first and second principle components
in PCA analysis.
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